Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States
You may also be interested in...
Lupin Evades U.S. Patent Battle With Warner Chilcott For Oral Contraceptives
WASHINGTON - Indian generic drug maker Lupin may have cleared a big hurdle in its pursuit to launch generic versions of Warner Chilcott's oral contraceptive drugs Loestrin 24 Fe and Femcon in the United States as the Irish company - specializing in dermatology and women's health products - decided to back out from a patent lawsuit it filed at the U.S. District Court of Maryland
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).